Stablecoin Development Corporation (SDEV)
XASE:SDEV
Top Page
Stablecoin Development Corp
(NYSE MKT:SDEV)
Select Model
Select Model
Rating:44Neutral
Price Target:
$1.50
▼(-49.15% Downside)
Action:ReiteratedDate:04/02/26
The score is held down primarily by very weak financial performance (revenue collapse, persistent losses, cash burn, and deeply negative equity). Technicals also remain bearish with price far below longer-term averages and negative MACD. Corporate events provide some support via new financing and a strategic pivot, but valuation remains constrained by continued unprofitability and no dividend support.
Positive Factors
Historically strong gross margins
Sustained mid-50s to mid-60s gross margins historically indicate strong product economics and unit profitability. If revenue recovery occurs, these margins provide structural leverage to drive operating profitability with disciplined SG&A, making a return to sustainable earnings feasible over months to a few years.
Negative Factors
Revenue collapse
A fall to zero reported revenue is an existential fundamental issue: it severs the link between prior unit economics and current operations. Rebuilding sales and distribution is a long, resource-intensive process; absent durable revenue restoration, margins and profitability cannot be realized.
Read all positive and negative factors
Positive Factors
Negative Factors
Historically strong gross margins
Sustained mid-50s to mid-60s gross margins historically indicate strong product economics and unit profitability. If revenue recovery occurs, these margins provide structural leverage to drive operating profitability with disciplined SG&A, making a return to sustainable earnings feasible over months to a few years.
Read all positive factors
Stablecoin Development Corp (SDEV) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$42.60M
Dividend YieldN/A
Average Volume (3M)545.01K
Price to Earnings (P/E)―
Beta (1Y)2.00
Revenue Growth-74.73%
EPS Growth95.81%
CountryUS
Employees4
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)N/A
Shares Outstanding26,625,029
10 Day Avg. Volume265,519
30 Day Avg. Volume545,011
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)-7.19
Price to Sales (P/S)0.00
P/FCF Ratio-19.47
Enterprise Value/Market Cap0.83
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-252.99
Enterprise Value/Ebitda-4.76
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.9
Revenue Forecast (FY)$15.80M
Stablecoin Development Corp Business Overview & Revenue Model
Company Description
Stablecoin Development Corp. engages in the development and sales of scientifically-created and clinically-proven eyecare and skincare. Its products include Avenova, NeutroPhase and DERMAdoctor. The company was founded on January 19, 2000 and is h...
How the Company Makes Money
NovaBay has historically generated revenue primarily from product sales of Avenova and related eye-care offerings. The company’s revenue model is centered on (1) selling finished goods through commercial channels (including direct-to-consumer and ...
Stablecoin Development Corp Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
9
Very Negative
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 10.46M | 14.40M | 10.20M |
| Gross Profit | -140.00K | -341.00K | 6.08M | 7.78M | 6.51M |
| EBITDA | -7.45M | -7.04M | -3.75M | -7.20M | -8.74M |
| Net Income | -33.34M | -7.22M | -6.14M | -10.61M | -5.82M |
Balance Sheet | |||||
| Total Assets | 10.65M | 45.91M | 50.42M | 16.40M | 23.98M |
| Cash, Cash Equivalents and Short-Term Investments | 7.96M | 430.00K | 2.92M | 5.36M | 7.50M |
| Total Debt | 776.00K | 1.67M | 2.61M | 2.04M | 551.00K |
| Total Liabilities | 33.47M | 46.03M | 47.10M | 5.84M | 13.81M |
| Stockholders Equity | -22.83M | -129.00K | 3.31M | 10.55M | 10.17M |
Cash Flow | |||||
| Free Cash Flow | -8.43M | -7.50M | -4.28M | -6.77M | -9.24M |
| Operating Cash Flow | -8.43M | -7.50M | -4.26M | -6.65M | -9.19M |
| Investing Cash Flow | 0.00 | 0.00 | -19.00K | -112.00K | -12.04M |
| Financing Cash Flow | 4.62M | 1.50M | 1.91M | 4.63M | 16.79M |
Stablecoin Development Corp Technical Analysis
Negative
2.95
Price Trends
2.44
Negative
13.06
Negative
8.89
Negative
Market Momentum
-0.70
Negative
39.92
Neutral
38.75
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SDEV, the sentiment is Negative. The current price of 2.95 is above the 20-day moving average (MA) of 1.49, above the 50-day MA of 2.44, and below the 200-day MA of 8.89, indicating a neutral trend. The MACD of -0.70 indicates Negative momentum. The RSI at 39.92 is Neutral, neither overbought nor oversold. The STOCH value of 38.75 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SDEV.
Stablecoin Development Corp Risk Analysis
Stablecoin Development Corp disclosed 26 risk factors in its most recent earnings report. Stablecoin Development Corp reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Stablecoin Development Corp Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $33.69M | -3.95 | -61.62% | ― | 4455.07% | 77.31% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $11.54M | -0.60 | -248.01% | ― | ― | 53.13% | |
45 Neutral | $4.80M | -0.04 | 9999.00% | ― | 12.45% | -544.23% | |
44 Neutral | $42.60M | ― | 1237.14% | ― | -74.73% | 95.81% | |
43 Neutral | $4.64M | -0.18 | -212.63% | ― | 192.72% | 83.61% |
* Healthcare Sector Average
SDEV
Stablecoin Development Corp
1.60
-0.25
-13.51%
SNGX
Soligenix
1.12
-0.84
-42.86%
JAGX
Jaguar Animal Health
0.37
-4.84
-92.92%
EVAX
Evaxion Biotech
4.04
2.62
184.51%
SPRC
SciSparc Ltd.
3.15
-53.98
-94.49%
SXTP
60 Degrees Pharmaceuticals, Inc.
1.76
-11.28
-86.50%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.